IRIS - Res&Arch Institutional Research Information System - Research & Archive

RICCIUTI, BIAGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 612
EU - Europa 348
AS - Asia 212
Totale 1.172
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 601
IE - Irlanda 137
IT - Italia 82
CN - Cina 60
SG - Singapore 56
HK - Hong Kong 50
VN - Vietnam 33
FI - Finlandia 27
RO - Romania 27
FR - Francia 17
RU - Federazione Russa 17
DE - Germania 15
CA - Canada 10
KR - Corea 8
UA - Ucraina 6
CH - Svizzera 5
GB - Regno Unito 3
GR - Grecia 3
SE - Svezia 3
UZ - Uzbekistan 3
IN - India 2
AT - Austria 1
BE - Belgio 1
DK - Danimarca 1
HU - Ungheria 1
MX - Messico 1
PL - Polonia 1
RS - Serbia 1
Totale 1.172
Salva come PNG Salva come JPEG
Città #
Chandler 179
Dublin 137
San Mateo 57
Hong Kong 50
Singapore 37
Boardman 36
Dong Ket 33
Altamura 31
Bucharest 27
Lawrence 27
Medford 27
Princeton 27
Beijing 24
Wilmington 19
Perugia 18
Helsinki 17
Des Moines 12
Ottawa 10
San Paolo di Civitate 9
Ann Arbor 8
Seoul 8
Andover 7
Saint Petersburg 7
Norwalk 5
Redwood City 5
Arezzo 4
Los Angeles 4
Munich 4
Nanjing 4
New York 4
Santa Clara 4
Redmond 3
Rome 3
Faenza 2
Paris 2
Simi Valley 2
Terni 2
Ashburn 1
Azcapotzalco 1
Brussels 1
Chicago 1
Esslingen am Neckar 1
Falls Church 1
Guttingen 1
Houston 1
Kunming 1
Lappeenranta 1
Lausanne 1
Mozzo 1
Mumbai 1
Nagold 1
Nanchang 1
Sterling 1
Szeged 1
Xian 1
Totale 873
Salva come PNG Salva come JPEG
Nome #
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 71
Non-coding RNAs in lung cancer 61
Antibody–drug conjugates for lung cancer in the era of personalized oncology 57
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence 57
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 56
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 53
Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications 53
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 52
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 51
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 48
Osimertinib 47
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 47
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 45
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 44
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 43
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 43
High density lipoprotein cholesterol and cancer: Marker or causative? 43
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 43
Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinking 42
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 42
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 39
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 39
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 39
High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art 38
Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy 36
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 28
Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy 26
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 15
Totale 1.258
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.965
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.965
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202053 0 0 0 0 4 3 2 12 7 16 9 0
2020/2021100 2 0 2 1 50 6 0 5 0 0 1 33
2021/2022201 1 38 1 3 3 3 3 55 4 22 28 40
2022/2023530 28 104 12 39 47 56 0 29 189 0 22 4
2023/2024199 11 26 19 4 2 1 38 1 15 6 43 33
2024/202575 9 30 36 0 0 0 0 0 0 0 0 0
Totale 1.258